Companies · REGN
Regeneron
AI-generated · informational only · not investment advice · verify before relying.
Latest analysis
Updated Jul 30, 2026
Regeneron Q2 2026: Dupixent hits $6B all-time high, Sanofi Development Balance repaid, driving step-up in collaboration profits from Q3 onward.
Regeneron's Q2 2026 results are defined by two structural inflections: Dupixent global net sales reaching $6.0 billion (+38% YoY), and the full repayment of the Sanofi Development Balance, which will meaningfully increase collaboration profit share beginning Q3 2026. Total revenues reached $4.3 billion, up 17% from Q2 2025, with non-GAAP EPS growing 11% to $14.29. The fianlimab Phase 3 trial failure in melanoma is the primary pipeline setback, while cemdisiran NDA acceptance under priority review (November 2026 PDUFA) and the Limerick manufacturing interruption resolution define the near-term risk-and-recovery narrative.
Tone: bullishRevenue
$14.3B
REGN 10-K · FY 2025
Employees
15,410
Revenue FY2024
$14.2B
Founded
1988
Profile
REGN 10-K Item 1 · Feb 4, 2026Regeneron Pharmaceuticals is a fully integrated biotechnology company that invents, develops, manufactures, and commercializes medicines for serious diseases including eye diseases, cancer, allergic and inflammatory conditions, cardiovascular disorders, and rare diseases. The company markets products primarily through collaborations with Sanofi and Bayer, with Dupixent and the EYLEA franchise as its primary revenue drivers. Regeneron also operates the Regeneron Genetics Center, a genomics subsidiary that has sequenced over three million samples to identify novel therapeutic targets.
Read filing description ↓ Collapse description ↑
Regeneron Pharmaceuticals, Inc. is a fully integrated biotechnology company that invents, develops, manufactures, and commercializes medicines for people with serious diseases. Our products and product candidates in development are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases, and rare diseases. Our core business strategy is to maintain a strong foundation in scientific research and drug development using our proprietary technologies, and to build on that foundation with our clinical development, manufacturing, and commercial capabilities. Our objective is to continue to advance as an integrated, multi-product biotechnology company that provides patients and medical professionals with important medicines for preventing and treating human diseases. We commercialize our products both in the United States and other countries through our commercial group, which includes experienced professionals in the fields of marketing, sales, professional education, patient education, reimbursement and market access, trade and distribution, commercial operations, commercial analytics, and market research. We sell our marketed products primarily to wholesalers, specialty distributors, pharmacies, hospitals, government agencies, physicians, and other healthcare providers. Our research and development efforts have led to numerous products that have received marketing approval and approximately 45 product candidates currently in clinical development, most of which were homegrown in our laboratories. We manage our business as one segment which includes all activities related to the discovery, development, and commercialization of medicines for serious diseases.
Primary products
- EYLEA HD (aflibercept) Injection 8 mg
- EYLEA (aflibercept) Injection
- Dupixent (dupilumab) Injection
- Libtayo (cemiplimab) Injection
- Praluent (alirocumab) Injection
- Kevzara (sarilumab) Injection
Business segments
End markets
Geographies
Named competitors
“Our ability to compete depends, to a great extent, on how fast we can develop safe and effective product candidates, complete clinical testing and approval processes, and supply commercial quantities of the product to the market.” Competitive position, as stated in the filing
Revenue commentary · FY 2025
Total revenues increased modestly from $14,202.0 million in 2024 to $14,342.9 million in 2025, as growth in collaboration revenue and other revenue offset a significant decline in net product sales driven by EYLEA biosimilar competition and a 42% decline in EYLEA U.S. net product sales.
The rest of REGN is for subscribers
Analysis, signals, diligence answers, M&A activity and every quote, each citing the filing it came from.